Personalized mRNA Cancer Vaccines: A New Era for Melanoma Treatment

Key Takeaways

• KEYNOTE-942 (NCT03897881) is a Phase 2 adjuvant study of mRNA-4157 plus pembrolizumab in high-risk melanoma; ClinicalTrials.gov lists actual enrollment of 267.
• Phase 3 V940-001 (NCT05933577) compares intismeran autogene plus pembrolizumab with pembrolizumab alone in resected high-risk melanoma; estimated enrollment about 1,089.
• Sponsors reported sustained recurrence-free survival benefit at median five-year follow-up (HR=0.510) in a January 20, 2026 company release—not yet a substitute for completed Phase 3 readout.
• Each patient’s vaccine is built from tumor neoantigens; manufacturing logistics remain a commercial bottleneck even if efficacy holds.

How do personalized mRNA vaccines work with Keytruda?

Tumor sequencing identifies patient-specific neoantigens. An mRNA construct encoding those antigens is manufactured and given to train T cells. Keytruda blocks PD-1 so those T cells are less likely to be shut down in the tumor microenvironment.

The combo is therefore two mechanisms: antigen-specific priming plus checkpoint blockade. Melanoma’s high mutation burden made it an early test bed for this design.

What does KEYNOTE-942 (NCT03897881) show so far?

ClinicalTrials.gov NCT03897881 titles the study as adjuvant mRNA-4157 with pembrolizumab in high-risk melanoma (KEYNOTE-942). Status is ACTIVE_NOT_RECRUITING, Phase 2, actual enrollment 267, start July 18, 2019, with ModernaTX as lead sponsor.

A January 20, 2026 Merck / Moderna release said median five-year follow-up still showed a 49% lower risk of recurrence or death versus Keytruda alone (HR=0.510; 95% CI 0.294–0.887; one-sided nominal p=0.0075). Treat that as sponsor-reported Phase 2b data pending fuller peer-reviewed presentation.

What is Phase 3 V940-001 testing?

NCT05933577 (V940-001) is a Phase 3 randomized study of intismeran autogene plus pembrolizumab versus pembrolizumab in people with high-risk melanoma after surgery. Registry details list Merck Sharp & Dohme as sponsor, estimated enrollment 1,089, start July 19, 2023, and primary completion estimated October 26, 2029.

• Primary endpoint focus: recurrence-free survival.
• Arms: combo versus pembrolizumab (± placebo vaccine as described on the registry).
• Setting: adjuvant, resected high-risk disease.
• Drug names in use: mRNA-4157 / V940 / intismeran autogene + Keytruda.

Why does this matter for BD and commercial teams?

If Phase 3 confirms KEYNOTE-942, adjuvant melanoma practice could add a personalized mRNA product on top of Keytruda—changing contracting, hospital pharmacy workflows, and tumor-sequencing turnaround times.

Even before approval, partnership models around neoantigen manufacturing capacity are strategic assets. Failures on logistics can erase clinical advantage.

Buyers should track three operational metrics alongside efficacy: days from biopsy to vaccine release, batch-failure rates, and how Keytruda dosing schedules sync with intramuscular vaccine visits. Those details decide whether a positive hazard ratio can scale across community oncology networks.

For investors, the Merck–Moderna alliance also sets a template for other checkpoint owners: own the PD-1 franchise, partner the individualized construct, and share Phase 3 risk. Competing mRNA oncology programs will be judged against the same KEYNOTE-942 and V940-001 bar on recurrence-free survival.

What remains unproven?

Phase 3 V940-001 has not reported a final primary-endpoint win that would support labeling. Cross-tumor “120 trials” type counts are not used here without a current registry snapshot tied to a dated query.

Overall survival and distant metastasis-free survival need mature Phase 3 data. Personalized manufacturing cost and vein-to-vein time are open commercial questions.

Related NovaPharma coverage

• Keytruda (pembrolizumab) drug profile
• Melanoma disease hub
• BioNTech Phase 1 pancreatic mRNA vaccine trial

Frequently Asked Questions

Primary Sources

1. ClinicalTrials.gov — NCT03897881 (KEYNOTE-942)
2. ClinicalTrials.gov — NCT05933577 (V940-001 Phase 3)
3. Merck — Jan 20, 2026 five-year KEYNOTE-942 update